These metabolites exhibited protective properties against non-alcoholic fatty liver disease (NAFLD) by mitigating lipid deposition effects, reversing liver weight loss, and reducing liver triglyceride content together with restoring lower levels of alanine transaminase (ALT) and aspartate aminotransferase (AST). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.